LNDC Landec Corp.

Lifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022

Lifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022

CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Lifecore” or the “Company”), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. (“Lifecore”) and Curation Foods, Inc. (“Curation Foods”), – today announced that Jim Hall, CEO of Landec Corporation & President of Lifecore, and John Morberg, CFO will be hosting a fireside chat at the Stephens Annual Investment Conference in Nashville, TN.

The Company will participate in a fireside chat on Thursday, November 17th at 8:00 AM CT. The live audio webcast will be available to all interested parties through a live audio webcast accessible on the Company's investor relations website at .

About Lifecore Biomedical

Lifecore Biomedical (Nasdaq: LNDC) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore’s website at .

Landec Corp. Contact Information:

Investor Relations

Jeff Sonnek

(646) 277-1263

 



EN
10/11/2022

Underlying

LNDCLandec Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Marke...

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum. Details regarding Lifecore’s participation are as follows: 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum Details: Mr. Josephs will be a featured speaker in a fireside chat...

March 10, 2026 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical to Report Financial Results for the Fourth Quarter...

Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026 Webcast Scheduled for Monday, March 16 at 8:30 a.m. Eastern CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and transition period ended December 31, 2025, on Monday, March 16, 2026, before the market opens. At 8:30 a.m. Eastern Time t...

March 9, 2026 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovat...

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clini...

March 4, 2026 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical to Participate at DCAT Week 2026

Lifecore Biomedical to Participate at DCAT Week 2026 CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City. Details regarding Lifecore’s participation are as follows: DCAT Week 2026Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and n...

February 17, 2026 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to tw...

January 16, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch